arcapta neohaler
Pharmaranks rates Arcapta Neohaler 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Arcapta Neohaler (Indacaterol Maleate) is a medication used to treat Pulmonary Emphysema, Chronic Bronchitis.
Indacaterol Maleate · by Novartis
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Indacaterol Maleate
- Form
- Powder
- Strength
- Indacaterol Maleate EQ 75MCG Base
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- pulmonary emphysema, chronic bronchitis
- Manufacturer
- Novartis
- FDA application
- NDA022383
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Powder
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Arcapta Neohaler treat?
- Arcapta Neohaler (Indacaterol Maleate) may be used to treat pulmonary emphysema, chronic bronchitis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Arcapta Neohaler rated?
- pharmaranks gives Arcapta Neohaler a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Arcapta Neohaler?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Arcapta Neohaler. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Arcapta Neohaler?
- Arcapta Neohaler is marketed by Novartis. You can see Novartis's full profile, rating, and other products on pharmaranks.
- Is Arcapta Neohaler a brand-name or generic drug?
- Arcapta Neohaler is a brand-name product with the active ingredient Indacaterol Maleate.
- Is Arcapta Neohaler available over the counter?
- No. Arcapta Neohaler is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Arcapta Neohaler come in?
- Arcapta Neohaler is currently marketed as powder, per the FDA's National Drug Code Directory.
- Is Arcapta Neohaler FDA-registered?
- Arcapta Neohaler is on record with the U.S. FDA under application number NDA022383. You can verify this on its official FDA label.
- Has Arcapta Neohaler been recalled by the FDA?
- Arcapta Neohaler has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Arcapta Neohaler safe?
- There's no single safe-or-not verdict. pharmaranks gives Arcapta Neohaler a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about INDACATEROL MALEATE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 785 reports naming INDACATEROL MALEATE — the active ingredient in Arcapta Neohaler, and the FDA flagged 99% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- dyspnoea315 reports
- asthma237 reports
- wheezing222 reports
- loss of personal independence in daily activities146 reports
- cough136 reports
- therapeutic product effect incomplete129 reports
- pneumonia119 reports
- sleep disorder due to a general medical condition116 reports
Read these as a signal, not a rate. A report does not mean INDACATEROL MALEATE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
atrovent hfa
Ipratropium Bromide
spiriva respimat
Tiotropium Bromide
striverdi respimat
Olodaterol Hydrochloride
spiriva
Tiotropium Bromide
incruse ellipta
Umeclidinium Bromide
Compare Arcapta Neohaler head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
arcapta neohaler
70/100